Passweg et al developed a risk score for a patient in the first chronic phase of CML treated by allogeneic hematopoietic stem cell transplant. It is based on the EBMT risk score. The authors are from the Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry.